2025 Set to Be a Breakout Year for siRNA as Funding and FDA Wins Pile Up

Published on Spencer Knight via LinkedIn

siRNA therapies are seeing renewed momentum, with major investments and regulatory wins announced across multiple companies:

• CRISPR Therapeutics partnered with Sirius Therapeutics in a $95M deal to advance clot-prevention siRNA therapies

• Alnylam and Sanofi secured FDA approval for Qlfitia™, the first siRNA therapy for Hemophilia A/B

• AbbVie x ADARx announced a $65M collaboration to develop gene silencing tools in immunology and oncology

• Atalanta Therapeutics raised $97M to support their di-siRNA platform targeting Huntington’s and KCNT1 epilepsy

Spencer Knight highlights siRNA's ability to silence hard-to-drug genes, deliver durable effects, and maintain infrequent dosing schedules, making it a standout modality across neurology, hematology, and rare disease.

Read the full post on LinkedIn:

👉 Spencer Knight: Breakthrough Year for siRNA Therapies

Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full details, please refer to the original article via the provided link.